Voices
Adjuvant Selpercatinib Supported as New Standard of Care in Early-Stage RET Fusion-Positive NSCLC – IASLC
Jonathan W. Goldman/ilcn.org

Adjuvant Selpercatinib Supported as New Standard of Care in Early-Stage RET Fusion-Positive NSCLC – IASLC

 International Association for the Study of Lung Cancer (IASLC) shared a post on LinkedIn:

“ASCO26 recap:

Dr. Jonathan W. Goldman shares how findings from the LIBRETTO-432 trial support adjuvant selpercatinib as a new standard of care for patients with early-stage RET fusion-positive NSCLC.

Read his insights now in ILCN.”

You can also read:

LIBRETTO-432 Trial at ASCO 2026 Plenary Session: Adjuvant Selpercatinib in RET Fusion-Positive NSCLC
Adjuvant Selpercatinib Supported as New Standard of Care in Early-Stage RET Fusion-Positive NSCLC - IASLC

ASCO26 cancer IASLC Jonathan W. Goldman LIBRETTO-432 Lung cancer NSCLC OncoDaily Oncology